You are here: Industry Insights > dolutegravir

News List

European Commission approves dispersible tablets to treat paediatric HIV europeanpharmaceuticalreview
January 14, 2021
Marketing authorisation in the EU has been given to Tivicay (dolutegravir) dispersible tablets to treat HIV in certain paediatric patients.
Study suggests dolutegravir is the optimal first-line HIV medication europeanpharmaceuticalreview
October 21, 2020
Researchers comparing dolutegravir to efavirenz suggest dolutegravir increases viral suppression and has similar rates of adverse events.
ViiV’s two-drug HIV regimen demonstrates long-term efficacy pharmatimes
October 10, 2020
ViiV Healthcare has released long-term data for its two-drug regimen of dolutegravir plus lamivudine, which continued to offer non-inferior efficacy compared to a three-drug regimen in HIV.
GSK's long-acting HIV injectable hits FDA snag fiercepharma
December 27, 2019
HIV patients looking for relief from the burden of daily pills will have to wait a little longer.GlaxoSmithKline’s ViiV Healthcare said that the FDA had rejected its long-acting HIV injection ...
WHO recommends dolutegravir as preferred HIV treatment option biospectrumasia
July 23, 2019
Based on new evidence assessing benefits and risks, the WHO recommends the use of the HIV drug dolutegravir (DTG) as the preferred first-line and second-line treatment for all populations, including pregnant women and those of childbearing potential.
EU nod for ViiV/Janssen's two-drug HIV regimen pharmatimes
July 13, 2018
ViiV Healthcare and Janssen have announced the approval of Juluca in Europe as the first two-drug regimen to treat some patients with HIV.
EU nod for ViiV/Janssen's two-drug HIV regimen pharmatimes
July 12, 2018
ViiV Healthcare and Janssen have announced the approval of Juluca in Europe as the first two-drug regimen to treat some patients with HIV.